-
-
-
-
-
-
-
Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access
-
-
-
-
-
-
-
Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
-
-
-
-
-
-
-
Emergent BioSolutions Reports First Quarter 2024 Financial Results
-
-
-
-
-
-
-
Emergent BioSolutions Reports Financial Results for Second Quarter 2023
-
-
-
-
-
-
-
Bavarian Nordic to Acquire Portfolio of Travel Vaccines from Emergent BioSolutions
-
-
-
-
-
-
-
Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach
-
-
-
-
-
-
-
Emergent BioSolutions Reports Financial Results for Second Quarter 2022
-
1,179,439 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

